More and more, artificial intelligence is becoming inseparable from drug development. But it needs to be well integrated with the right people and support technologies in order to be successful, according to Josep Bassaganya-Riera, the founder and CEO of Nimmune Biopharma Inc. Nimmune has leveraged methods of AI-enabled drug discovery to develop a number of late-stage therapeutics using a strategic model Bassaganya-Riera first developed at Landos Biopharma Inc., a previous venture which was sold to Abbvie in 2024. As the founder of several other companies, Bassaganya-Riera has more than 20 years in the industry and he shared his insights and experience on the podcast about the crucial importance of getting technology and people in balance. The key, he said, is to have the right people in the same room interacting with each other and the technology.